Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting

NEXT STORY
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
PREV STORY
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global In-vitro Diagnostics Market Report 2019-2023: Market will Register a CAGR of Almost 7% – Adoption of Advanced Treatment Solutions to Gain Traction

Dublin, Jan. 08, 2019 (GLOBE NEWSWIRE) -- The "Global In-vitro Diagnostics Market 2019-2023" report ...

author_avatar
NASDAQ Market News

Targovax ASA moves share listing to Oslo Børs

Oslo, Norway, 23 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a ...

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Provides Corporate Update Highlighting Upcoming Milestones and Events

BEVERLY, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a ...

author_avatar
NASDAQ Market News